Perspective Therapeutics (NYSE:CATX) Price Target Cut to $16.00 by Analysts at Oppenheimer

Perspective Therapeutics (NYSE:CATX - Get Free Report) had its target price dropped by equities research analysts at Oppenheimer from $22.00 to $16.00 in a report issued on Friday,Benzinga reports. The brokerage currently has an "outperform" rating on the stock. Oppenheimer's price target would indicate a potential upside of 361.10% from the company's current price.

CATX has been the subject of a number of other reports. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Perspective Therapeutics in a research report on Monday, September 9th. Royal Bank of Canada lowered their target price on Perspective Therapeutics from $29.00 to $27.00 and set an "outperform" rating for the company in a research note on Friday, August 16th. UBS Group assumed coverage on Perspective Therapeutics in a report on Thursday, October 24th. They issued a "buy" rating and a $20.00 price target for the company. Truist Financial initiated coverage on shares of Perspective Therapeutics in a research report on Wednesday, September 25th. They issued a "buy" rating and a $21.00 price objective for the company. Finally, Wedbush reissued an "outperform" rating and set a $11.00 target price (down from $20.00) on shares of Perspective Therapeutics in a research report on Thursday. Nine research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of $19.43.

Perspective Therapeutics Price Performance

Shares of Perspective Therapeutics stock traded up $0.47 during trading hours on Friday, reaching $3.47. The stock had a trading volume of 9,654,293 shares, compared to its average volume of 1,478,868. Perspective Therapeutics has a 1 year low of $2.28 and a 1 year high of $19.05. The business's 50 day simple moving average is $11.52.

Perspective Therapeutics (NYSE:CATX - Get Free Report) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.21) EPS for the quarter, meeting the consensus estimate of ($0.21). Perspective Therapeutics had a negative net margin of 4,096.66% and a negative return on equity of 27.40%. The firm had revenue of $0.37 million for the quarter. Research analysts anticipate that Perspective Therapeutics will post -0.86 EPS for the current year.

Institutional Trading of Perspective Therapeutics

A number of hedge funds have recently made changes to their positions in CATX. nVerses Capital LLC bought a new position in Perspective Therapeutics during the 3rd quarter valued at $57,000. US Bancorp DE grew its stake in Perspective Therapeutics by 142.7% in the third quarter. US Bancorp DE now owns 6,576 shares of the company's stock worth $88,000 after purchasing an additional 3,866 shares in the last quarter. Victory Capital Management Inc. bought a new stake in Perspective Therapeutics in the second quarter valued at about $117,000. Point72 DIFC Ltd bought a new stake in Perspective Therapeutics in the second quarter valued at about $118,000. Finally, Intech Investment Management LLC bought a new position in Perspective Therapeutics during the 3rd quarter worth approximately $137,000. Institutional investors and hedge funds own 54.66% of the company's stock.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.